Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan

Doukou Essien Samuel; Toni Thomas D'Aquin; N’din Jean-Louis Philippe; Dechi Jean-Jacques Renaud; Gogbe Leto Olivier; N’Guessan Jean François; Chenal Henri; Messou Kouassi Eugene; Lohoues Esmel Claude; Ouassa Timothée

doi:doi:10.11648/j.ajbio.20231104.13

Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan

Doukou Essien Samuel, Toni Thomas D'Aquin, N’din Jean-Louis Philippe, Dechi Jean-Jacques Renaud, Gogbe Leto Olivier, N’Guessan Jean François, Chenal Henri, Messou Kouassi Eugene, Lohoues Esmel Claude, Ouassa Timothée

Published in American Journal of BioScience (Volume 11, Issue 4)

Received: 11 July 2023 Accepted: 1 August 2023 Published: 9 August 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Mutant selection is due to the high rate of viral replication and lack of proofreading activity in the hepatitis B virus (HBV) polymerase thus leading to the generation of mutations in HBV. However naturally occurring HBV strains carrying primary drug resistance mutations are very rare in the absence of prior treatment. Monitoring changes in primary and secondary resistance mutations in patients who haven't been treated is crucial in order to optimize and promote the best treatment, to obtain a sustained virological response (SVR) and therefore, reduce the progression to cirrhosis and later to hepatocellular carcinoma (HCC). The main purpose of this research was to evaluate the resistance of HBV to antivirals and show the genetic variability of HBV in a population of blood donors, carrying HBs antigen, naïve to anti-HBV treatment in Abidjan. A descriptive and analytical cross-sectional method was used to establish the molecular profile and to identify the polymorphism of HBV in treatment-naïve infected study participants. Adults blood donors, of any sex, with a positive result for HBsAg, naïve to any antiviral treatment but with an HBV viral load superior to 1000 IU/ml were included. The ABI 3130 Avant sequencer (Applied Biosystems, Courtaboeuf, France) was used to sequence the polymerase (pol) gene to determine HBV resistance genotypes. Fifty-three (N=53) blood donors infected with HBV (HBs Ag positive) were screened. All patients were naïve to any antiviral treatment. Of all these patients, 30 (56.6%) blood donors, carrying HBsAg with a viral load superior to 1000 IU/mL were included in the study. The median age was 34 years old (21-52). The median viral load was 6561 IU/mL (103 – 1.65 x 109). Two mutations of a single base, notably A181T and A181S were highlighted in this study. The A181T mutation was associated with resistance to adefovir, lamivudine and telbivudine. As for the A181S mutation, it was associated with resistance to adefovir only. Analysis of phylogenetic trees obtained by sequencing confirmed the circulation of 2 genotypes: E (22; 92%) and A (2; 8%). The circulation of genotypes A and E of HBV in Côte d'Ivoire has been confirmed by this study, with an estimated genotypic mutation prevalence of 8%. The resistance of HBV to some antiretroviral drugs in the class of HBV polymerase inhibitors, such as lamivudine (3TC), telbivudine (LdT) adefovir (ADV) may be attributed to these mutations.

Published in	American Journal of BioScience (Volume 11, Issue 4)
DOI	10.11648/j.ajbio.20231104.13
Page(s)	92-97
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

HBsAg, Hepatitis B, Primary Resistance

References

[1]	WHO. 2017. New data on hepatitis underscore the urgent need for a global response. Who. int/fr/news-rom/detail/21-04-2017. 4 p.
[2]	Yang S, Ding C, Cui Y, Cui Y, Wu J., Yu C., Chen P., Xu K., Deng M., Yiping Li Y., Liu J., Yin P., Ren W., Qiu Y., Cao Q., Zhou Y., Yao J., Ruan B., Ren J. & Li L. 2017. Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open. (7) 1-8.
[3]	Hadad SE, Alakilli S., Rabah S. & Sabir J. 2018. Sequence analysis of sub-genotype D hepatitis B surface antigens isolated from Jeddah, Saudi Arabia. Saudi Journal of Biological Sciences. 35: 838-845.
[4]	Ambachew H, Zheng M, Pappoe F, Shen J. & Xu Y. 2018. Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLOS ONE. 13 (2): 1-14.
[5]	Enel, C., Desgrées du Loû, A., N'Dri Yoman, T. C. Danel &J. Larmarange. 2015. Viral hepatitis B and C in Côte d'Ivoire: the urgent need to revitalize the fight. African Journal of Hepato-Gastroenterology. 9 (3) 94–98.
[6]	Ya Fu, Songhang Wu, Yuhai Hue, Tianbin Chen, Yongbin Zeng, Can Liu and Qishui Ou. 2020. Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients. Emerging Microbes & Infections, VOL. 9. 2381-2393pp. https://doi.org/10.1080/22221751.2020.1835446
[7]	Rapti I, Hadziyannis S. 2015. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol. 18 mai 2015; 7 (8): 1064-73.
[8]	Xu J, Wu B, Wang JH, Huang L, Wang Dy, Zhao L. 2015. Pre-Existing Mutations in Reverse Transcriptase of Hepatitis B Virus in Treatment-Naive Chinese Patients with Chronic Hepatitis B. PLoS ONE 10 (3): e0117429.12 pages. doi: 10.1371/journal.pone.0117429.
[9]	Reza Nezhadi Masoumeh, Alireza Mohebbi, Fatemeh Sana Askari, Seyyede Delafruz Hosseini, Alijan Tabarrae. 2019. Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naive chronically infected patients. Virus Dis. 30 (2): 219–226 https://doi.org/10.1007/s13337-018-00510-5
[10]	N'din Philippe JL., Thomas A. Toni, Renaud JJ. Dechi, Léto O. Gogbe, Jean F. N'guessan, Emmanuel Brou, Ahoua Aguia, Kouadio Kouakou, Henri Chenal, Massara Camara-Cisse. 2018. Molecular Characterization and Resistance of Hepatitis B Virus to Polymerase Inhibitors in HIV Co-Infected Patients in Abidjan, Côte d'Ivoire, West Africa. International Journal of Virology and Molecular Biology 7 (2): 27-32. DOI: 10.5923/j.ijvmb.20180702.01.
[11]	Kumar, Sudhir, Glen Stecher, et Koichiro Tamura. 2016. «MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets». Molecular Biology and Evolution 33 (7): 1870-74. https://doi.org/10.1093/molbev/msw054.
[12]	Joseph C. Forbi YousrBen, Ayeda Guo, liang Xiaa, Gilberto Vaughana, Jan Drobeniuca, William M. Switzerb & Yury E. Khudyakov. 2013. Disparate distribution of hepatitis B virus genotypes in four sub-Saharan African countries. Journal of Clinical Virology Volume 58, Issue 1, September 2013, Pages 59-66.
[13]	Lawson-Ananissoh LM KA Attia D. Diallo S. Doffou YH Kissi D. Bangoura D. Kouame KA Mahassadi F. Yao-Bathaix T. N Yoman. 2017. Distribution and Clinical Implications of the Genotypes of the Hepatitis B Virus in 33 Chronic Carriers of Hepatitis B Virus in Ivory Coast. J. Afr. Hepatol. Gastroenterol. DOI: 10.1007/s12157-017-0726-4. 5 pages.
[14]	Gogbe LO, Toni Ta, Dechi JJ R, N'din JL P, Brou E, Fieni F, Aby R, Chenal H, N'guessan J D. 2020. Resistance of HBV to nucleoside reverse transcriptase inhibitors and its impact on surface antigen in hbv-hiv co-infected patients in Abidjan. International Journal of Biochemistry, Bioinformatics and Biotechnology Studies 5 (2): 23-40.
[15]	Xizhan Xu, Kuanhui Xiang, Mingze Su, Yao Li, Wei Ji, Yutang Li, Hui Zhuang and Tong Li. 2017. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 9, 199; 14p.
[16]	Pacheco Sidelcina Rugieri, Maria Isabel Magalhães, Andrade dos Santos, Andréas Stocker, Marie-Alice Sant'Anna Zarifé, Marie-Isabel Schinoni, Raymundo Parana, Mitermayer Galvão dos Réis, Luciano Kalabric Silva. 2017. HBV genotyping and mutation monitoring resistance in treatment-naïve patients with chronic hepatitis B. J. Afr. Hepatol. Gastroenterol. DOI: 10.1007/s12157-017-0726-4. 4 pages.
[17]	Zhao ouyun, Jianhua Wu, Lijun Sun, Guangzhong Liu, Bo Li, Yi Zheng, Xiaodong Li, Junxiu Tao, 2016. Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. braz j foul dis. 2 0 (2): 173–178.
[18]	Bin Zhu, Tianbao Wang, Xiaoxia Wei, Ya Zhuo, Amin Liu, Guangwen Zhang. 2017. Accumulation of mutations in reverse transcriptase hepatitis B virus is associated with the severity of liver disease in Treatment-naïve Chinese patients with chronic hepatitis B. Adv Clin Exp Med.; 26 (7): 1123–1129.

Cite This Article

Plain Text BibTeX RIS

APA Style

Doukou Essien Samuel, Toni Thomas D'Aquin, N’din Jean-Louis Philippe, Dechi Jean-Jacques Renaud, Gogbe Leto Olivier, et al. (2023). Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. American Journal of BioScience, 11(4), 92-97. https://doi.org/10.11648/j.ajbio.20231104.13

Copy | Download

ACS Style

Doukou Essien Samuel; Toni Thomas D'Aquin; N’din Jean-Louis Philippe; Dechi Jean-Jacques Renaud; Gogbe Leto Olivier, et al. Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. Am. J. BioScience 2023, 11(4), 92-97. doi: 10.11648/j.ajbio.20231104.13

Copy | Download

AMA Style

Doukou Essien Samuel, Toni Thomas D'Aquin, N’din Jean-Louis Philippe, Dechi Jean-Jacques Renaud, Gogbe Leto Olivier, et al. Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. Am J BioScience. 2023;11(4):92-97. doi: 10.11648/j.ajbio.20231104.13

Copy | Download

@article{10.11648/j.ajbio.20231104.13,
  author = {Doukou Essien Samuel and Toni Thomas D'Aquin and N’din Jean-Louis Philippe and Dechi Jean-Jacques Renaud and Gogbe Leto Olivier and N’Guessan Jean François and Chenal Henri and Messou Kouassi Eugene and Lohoues Esmel Claude and Ouassa Timothée},
  title = {Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan},
  journal = {American Journal of BioScience},
  volume = {11},
  number = {4},
  pages = {92-97},
  doi = {10.11648/j.ajbio.20231104.13},
  url = {https://doi.org/10.11648/j.ajbio.20231104.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbio.20231104.13},
  abstract = {Mutant selection is due to the high rate of viral replication and lack of proofreading activity in the hepatitis B virus (HBV) polymerase thus leading to the generation of mutations in HBV. However naturally occurring HBV strains carrying primary drug resistance mutations are very rare in the absence of prior treatment. Monitoring changes in primary and secondary resistance mutations in patients who haven't been treated is crucial in order to optimize and promote the best treatment, to obtain a sustained virological response (SVR) and therefore, reduce the progression to cirrhosis and later to hepatocellular carcinoma (HCC). The main purpose of this research was to evaluate the resistance of HBV to antivirals and show the genetic variability of HBV in a population of blood donors, carrying HBs antigen, naïve to anti-HBV treatment in Abidjan. A descriptive and analytical cross-sectional method was used to establish the molecular profile and to identify the polymorphism of HBV in treatment-naïve infected study participants. Adults blood donors, of any sex, with a positive result for HBsAg, naïve to any antiviral treatment but with an HBV viral load superior to 1000 IU/ml were included. The ABI 3130 Avant sequencer (Applied Biosystems, Courtaboeuf, France) was used to sequence the polymerase (pol) gene to determine HBV resistance genotypes. Fifty-three (N=53) blood donors infected with HBV (HBs Ag positive) were screened. All patients were naïve to any antiviral treatment. Of all these patients, 30 (56.6%) blood donors, carrying HBsAg with a viral load superior to 1000 IU/mL were included in the study. The median age was 34 years old (21-52). The median viral load was 6561 IU/mL (103 – 1.65 x 109). Two mutations of a single base, notably A181T and A181S were highlighted in this study. The A181T mutation was associated with resistance to adefovir, lamivudine and telbivudine. As for the A181S mutation, it was associated with resistance to adefovir only. Analysis of phylogenetic trees obtained by sequencing confirmed the circulation of 2 genotypes: E (22; 92%) and A (2; 8%). The circulation of genotypes A and E of HBV in Côte d'Ivoire has been confirmed by this study, with an estimated genotypic mutation prevalence of 8%. The resistance of HBV to some antiretroviral drugs in the class of HBV polymerase inhibitors, such as lamivudine (3TC), telbivudine (LdT) adefovir (ADV) may be attributed to these mutations.},
 year = {2023}
}

Copy | Download

TY - JOUR
T1 - Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan
AU - Doukou Essien Samuel
AU - Toni Thomas D'Aquin
AU - N’din Jean-Louis Philippe
AU - Dechi Jean-Jacques Renaud
AU - Gogbe Leto Olivier
AU - N’Guessan Jean François
AU - Chenal Henri
AU - Messou Kouassi Eugene
AU - Lohoues Esmel Claude
AU - Ouassa Timothée
Y1 - 2023/08/09
PY - 2023
N1 - https://doi.org/10.11648/j.ajbio.20231104.13
DO - 10.11648/j.ajbio.20231104.13
T2 - American Journal of BioScience
JF - American Journal of BioScience
JO - American Journal of BioScience
SP - 92
EP - 97
PB - Science Publishing Group
SN - 2330-0167
UR - https://doi.org/10.11648/j.ajbio.20231104.13
AB - Mutant selection is due to the high rate of viral replication and lack of proofreading activity in the hepatitis B virus (HBV) polymerase thus leading to the generation of mutations in HBV. However naturally occurring HBV strains carrying primary drug resistance mutations are very rare in the absence of prior treatment. Monitoring changes in primary and secondary resistance mutations in patients who haven't been treated is crucial in order to optimize and promote the best treatment, to obtain a sustained virological response (SVR) and therefore, reduce the progression to cirrhosis and later to hepatocellular carcinoma (HCC). The main purpose of this research was to evaluate the resistance of HBV to antivirals and show the genetic variability of HBV in a population of blood donors, carrying HBs antigen, naïve to anti-HBV treatment in Abidjan. A descriptive and analytical cross-sectional method was used to establish the molecular profile and to identify the polymorphism of HBV in treatment-naïve infected study participants. Adults blood donors, of any sex, with a positive result for HBsAg, naïve to any antiviral treatment but with an HBV viral load superior to 1000 IU/ml were included. The ABI 3130 Avant sequencer (Applied Biosystems, Courtaboeuf, France) was used to sequence the polymerase (pol) gene to determine HBV resistance genotypes. Fifty-three (N=53) blood donors infected with HBV (HBs Ag positive) were screened. All patients were naïve to any antiviral treatment. Of all these patients, 30 (56.6%) blood donors, carrying HBsAg with a viral load superior to 1000 IU/mL were included in the study. The median age was 34 years old (21-52). The median viral load was 6561 IU/mL (103 – 1.65 x 109). Two mutations of a single base, notably A181T and A181S were highlighted in this study. The A181T mutation was associated with resistance to adefovir, lamivudine and telbivudine. As for the A181S mutation, it was associated with resistance to adefovir only. Analysis of phylogenetic trees obtained by sequencing confirmed the circulation of 2 genotypes: E (22; 92%) and A (2; 8%). The circulation of genotypes A and E of HBV in Côte d'Ivoire has been confirmed by this study, with an estimated genotypic mutation prevalence of 8%. The resistance of HBV to some antiretroviral drugs in the class of HBV polymerase inhibitors, such as lamivudine (3TC), telbivudine (LdT) adefovir (ADV) may be attributed to these mutations.
VL - 11
IS - 4
ER -

Copy | Download

Author Information

Doukou Essien Samuel

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
Toni Thomas D'Aquin

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
N’din Jean-Louis Philippe

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
Dechi Jean-Jacques Renaud

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
Gogbe Leto Olivier

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
N’Guessan Jean François

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
Chenal Henri

Center Integrated of Research Bioclinical of Abidjan (CIRBA), Abidjan, Côte d’Ivoire
Messou Kouassi Eugene

Care, Research and Training Center (CePReF), Abidjan, Côte d’Ivoire
Lohoues Esmel Claude

Biochemistry Laboratory of Medical Sciences Department, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
Ouassa Timothée

Pharmaceutical and Biological Sciences Department, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Doukou Essien Samuel, Toni Thomas D'Aquin, N’din Jean-Louis Philippe, Dechi Jean-Jacques Renaud, Gogbe Leto Olivier, et al. (2023). Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. American Journal of BioScience, 11(4), 92-97. https://doi.org/10.11648/j.ajbio.20231104.13

Copy | Download

ACS Style

Doukou Essien Samuel; Toni Thomas D'Aquin; N’din Jean-Louis Philippe; Dechi Jean-Jacques Renaud; Gogbe Leto Olivier, et al. Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. Am. J. BioScience 2023, 11(4), 92-97. doi: 10.11648/j.ajbio.20231104.13

Copy | Download

AMA Style

Doukou Essien Samuel, Toni Thomas D'Aquin, N’din Jean-Louis Philippe, Dechi Jean-Jacques Renaud, Gogbe Leto Olivier, et al. Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan. Am J BioScience. 2023;11(4):92-97. doi: 10.11648/j.ajbio.20231104.13

Copy | Download

@article{10.11648/j.ajbio.20231104.13,
  author = {Doukou Essien Samuel and Toni Thomas D'Aquin and N’din Jean-Louis Philippe and Dechi Jean-Jacques Renaud and Gogbe Leto Olivier and N’Guessan Jean François and Chenal Henri and Messou Kouassi Eugene and Lohoues Esmel Claude and Ouassa Timothée},
  title = {Molecular Characterization and Resistance Profile of the Hepatitis B Virus to Polymerase Inhibitors in Infected Treatment-Naïve Patients in Abidjan},
  journal = {American Journal of BioScience},
  volume = {11},
  number = {4},
  pages = {92-97},
  doi = {10.11648/j.ajbio.20231104.13},
  url = {https://doi.org/10.11648/j.ajbio.20231104.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbio.20231104.13},
  abstract = {Mutant selection is due to the high rate of viral replication and lack of proofreading activity in the hepatitis B virus (HBV) polymerase thus leading to the generation of mutations in HBV. However naturally occurring HBV strains carrying primary drug resistance mutations are very rare in the absence of prior treatment. Monitoring changes in primary and secondary resistance mutations in patients who haven't been treated is crucial in order to optimize and promote the best treatment, to obtain a sustained virological response (SVR) and therefore, reduce the progression to cirrhosis and later to hepatocellular carcinoma (HCC). The main purpose of this research was to evaluate the resistance of HBV to antivirals and show the genetic variability of HBV in a population of blood donors, carrying HBs antigen, naïve to anti-HBV treatment in Abidjan. A descriptive and analytical cross-sectional method was used to establish the molecular profile and to identify the polymorphism of HBV in treatment-naïve infected study participants. Adults blood donors, of any sex, with a positive result for HBsAg, naïve to any antiviral treatment but with an HBV viral load superior to 1000 IU/ml were included. The ABI 3130 Avant sequencer (Applied Biosystems, Courtaboeuf, France) was used to sequence the polymerase (pol) gene to determine HBV resistance genotypes. Fifty-three (N=53) blood donors infected with HBV (HBs Ag positive) were screened. All patients were naïve to any antiviral treatment. Of all these patients, 30 (56.6%) blood donors, carrying HBsAg with a viral load superior to 1000 IU/mL were included in the study. The median age was 34 years old (21-52). The median viral load was 6561 IU/mL (103 – 1.65 x 109). Two mutations of a single base, notably A181T and A181S were highlighted in this study. The A181T mutation was associated with resistance to adefovir, lamivudine and telbivudine. As for the A181S mutation, it was associated with resistance to adefovir only. Analysis of phylogenetic trees obtained by sequencing confirmed the circulation of 2 genotypes: E (22; 92%) and A (2; 8%). The circulation of genotypes A and E of HBV in Côte d'Ivoire has been confirmed by this study, with an estimated genotypic mutation prevalence of 8%. The resistance of HBV to some antiretroviral drugs in the class of HBV polymerase inhibitors, such as lamivudine (3TC), telbivudine (LdT) adefovir (ADV) may be attributed to these mutations.},
 year = {2023}
}

Copy | Download